Skip to main content
. Author manuscript; available in PMC: 2023 Aug 23.
Published in final edited form as: N Engl J Med. 2023 Feb 16;388(8):719–732. doi: 10.1056/NEJMoa2214676

Figure 2. Comparison of Progression-free Survival between Rucaparib and Control Medications in the BRCA Subgroup.

Figure 2.

Shown are Kaplan–Meier curves for rucaparib as compared with a control medication (docetaxel or a second-generation androgen-receptor pathway inhibitor [ARPI]) in the BRCA subgroup. The widths of the 95% confidence intervals were not adjusted for multiplicity and cannot be used in place of hypothesis testing.